反応式
[N:1]1[CH:2]=[CH:3][N:4]2[C:9]([NH2:10])=[CH:8][CH:7]=[CH:6][C:5]=12.C1C(=O)N(OC(ON2C(=O)CCC2=O)=O)[C:13](=[O:14])C1.Cl.[Cl:30][C:31]1[CH:50]=[CH:49][C:34]([O:35][C:36]2[CH:37]=[C:38]([CH:46]=[CH:47][CH:48]=2)[CH2:39][N:40]2[CH2:45][CH2:44][NH:43][CH2:42][CH2:41]2)=[CH:33][CH:32]=1.C(N(C(C)C)CC)(C)C>C(Cl)Cl.CN(C1C=CN=CC=1)C.CCOC(C)=O>[N:1]1[CH:2]=[CH:3][N:4]2[C:9]([NH:10][C:13]([N:43]3[CH2:44][CH2:45][N:40]([CH2:39][C:38]4[CH:46]=[CH:47][CH:48]=[C:36]([O:35][C:34]5[CH:49]=[CH:50][C:31]([Cl:30])=[CH:32][CH:33]=5)[CH:37]=4)[CH2:41][CH2:42]3)=[O:14])=[CH:8][CH:7]=[CH:6][C:5]=12参加物
反応物 4
生成物 1
試薬・触媒・溶媒 3
実験手順
To a solution of imidazo[1,2-a]pyridin-5-ylamine (56.0 mg, 0.421 mmol) in CH2Cl2 (2.0 mL) were added N,N′-disuccinimidyl carbonate (108 mg, 0.421 mmol) and DMAP (51.0 mg, 0.417 mmol). The reaction mixture was stirred at rt for 6 h, then treated with 1-[3-(4-chloro-phenoxy)-benzyl]-piperazine hydrochloride (158 mg, 0.420 mmol) and diisopropylethylamine (109 mg, 0.840 mmol) and stirred for an additional 16 h at rt. The reaction mixture was diluted with EtOAc and extracted with H2O then saturated aqueous NaCl. The organic layer was dried (MgSO4), and concentrated. The crude residue was purified (FCC, 2 N NH3 in MeOH/DCM) to give 4-[3-(4-chloro-phenoxy)-benzyl]-piperazine-1-carboxylic acid imidazo[1,2-a]pyridin-5-ylamide (90.0 mg, 46%). MS (ESI+): calcd for C25H24ClN5O2 m/z 461.17. found 462.2 (M+H)+. 1H NMR (d6-DMSO): 9.21 (br s, 1H), 7.57 (s, 1H), 7.54 (d, J=1.2, 1H), 7.47-7.35 (m, 4H), 7.23 (dd, J=9.0, 7.2, 1H), 7.15 (d, J=7.6, 1H), 7.06-7.01 (m, 3H), 6.94 (dd, J=8.1, 1.9, 1H), 6.73 (d, J=7.1, 1H), 3.54 (s, 2H), 3.52-3.45 (m, 4H), 2.46-2.40 (m, 4H).
後処理
- stirringstirred for an additional 16 h at rt
- extractionextracted with H2O
- dry with materialThe organic layer was dried (MgSO4)
- concentrationconcentrated
- customThe crude residue was purified (FCC, 2 N NH3 in MeOH/DCM)
出典と根拠
- ORDレコード
- ord-32e3a6b6b4894900a92c487deb3e8c77
- 出典データセット
- uspto-grants-2013_06
- 特許番号
- US08461159B2
関連ノート
読み込み中…